Global Biologics Contract Manufacturing Market Strategic Research Report

The global biologics contract manufacturing market occupied a central position in the life sciences supply chain in 2024, valued at approximately USD 28.6 billion and representing one of the most capital-intensive and technically demanding segments of pharmaceutical outsourcing. Biologics — encompassing monoclonal antibodies, recombinant proteins, vaccines, gene and cell therapies, and biosimilars — require highly specialized production infrastructure, stringent cold-chain logistics, and regulatory expertise that most innovator companies increasingly prefer to outsource rather than replicate internally. As biologic drugs now account for more than half of the top-selling pharmaceutical products globally, the contract development and manufacturing organization (CDMO) sector has emerged as a structural backbone of drug commercialization, attracting sustained investment from private equity, sovereign wealth funds, and strategic acquirers alike.

Growth in this market is propelled by three forces operating simultaneously. First, the accelerating approval cadence of novel biologic modalities — particularly antibody-drug conjugates (ADCs), mRNA-based therapeutics, and CAR-T cell therapies — is generating urgent demand for specialized manufacturing capacity that the industry does not yet have at sufficient scale, compelling biotech sponsors to rely almost entirely on external manufacturers. Second, the biosimilars wave, particularly in North America and Europe where reference biologics worth over USD 80 billion in annual sales faced patent expiration between 2021 and 2026, is driving high-volume manufacturing demand as biosimilar developers require cost-efficient upstream and downstream processing at commercial scale. The principal restraint on market expansion is the chronic shortage of skilled bioprocess engineers and quality assurance professionals, combined with the multi-year lead times and billion-dollar capital outlays required to commission new large-scale mammalian cell culture or viral vector manufacturing suites, creating meaningful capacity bottlenecks that delay client programs and compress margins.

This report delivers a granular, forecast-driven analysis of the global biologics contract manufacturing market across the 2025–2032 period, with a 2024 base year. It segments the market by molecule type, by service type, by expression system, and by end-use therapeutic application, and provides country-level forecasts for the United States, Germany, China, South Korea, India, and Switzerland. Corporate strategy teams evaluating build-versus-buy decisions, investment analysts conducting CDMO sector diligence, M&A advisors assessing target valuations, and procurement managers benchmarking outsourcing options will find actionable intelligence throughout.